Which has preferable earnings and valuation, HQY or DXCM?

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthEquity $1.31B 6.09 $215.20M $2.67 35.83 DexCom $4.66B 6.32 $836.30M $2.34 32.63

Is HQY or DXCM more profitable?

DexCom has a net margin of 19.31% compared to HealthEquity's net margin of 17.25%. DexCom's return on equity of 33.33% beat HealthEquity's return on equity. Company Net Margins Return on Equity Return on Assets HealthEquity 17.25% 14.75% 9.22% DexCom 19.31% 33.33% 13.19%

Does the media favor HQY or DXCM?

In the previous week, DexCom had 12 more articles in the media than HealthEquity. MarketBeat recorded 19 mentions for DexCom and 7 mentions for HealthEquity. DexCom's average media sentiment score of 0.93 beat HealthEquity's score of 0.82 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, DXCM or PODD?

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DexCom $4.66B 6.32 $836.30M $2.34 32.63 Insulet $2.71B 4.14 $247.10M $4.30 37.69

Is DXCM or PODD more profitable?

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets DexCom 19.31% 33.33% 13.19% Insulet 10.44% 26.87% 12.01%

Does the media refer more to DXCM or PODD?

In the previous week, Insulet had 31 more articles in the media than DexCom. MarketBeat recorded 50 mentions for Insulet and 19 mentions for DexCom. DexCom's average media sentiment score of 0.93 beat Insulet's score of 0.23 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 8 Very Positive mention(s) 2 Positive mention(s) 34 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, ABT or DXCM?

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abbott Laboratories $44.33B 3.62 $6.52B $3.57 25.77 DexCom $4.66B 6.32 $836.30M $2.34 32.63

Is ABT or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Abbott Laboratories' net margin of 13.90%. DexCom's return on equity of 33.33% beat Abbott Laboratories' return on equity. Company Net Margins Return on Equity Return on Assets Abbott Laboratories 13.90% 17.62% 10.01% DexCom 19.31% 33.33% 13.19%

Does the media favor ABT or DXCM?

In the previous week, Abbott Laboratories had 17 more articles in the media than DexCom. MarketBeat recorded 36 mentions for Abbott Laboratories and 19 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.29 beat DexCom's score of 0.93 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 28 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMN or DXCM?

In the previous week, DexCom had 2 more articles in the media than AMN Healthcare Services. MarketBeat recorded 19 mentions for DexCom and 17 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 0.93 beat AMN Healthcare Services' score of 0.38 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral DexCom 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ITGR or DXCM?

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.85B 1.77 $102.81M $4.01 24.04 DexCom $4.66B 6.32 $836.30M $2.34 32.63

Is ITGR or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Integer's net margin of 7.64%. DexCom's return on equity of 33.33% beat Integer's return on equity. Company Net Margins Return on Equity Return on Assets Integer 7.64% 12.83% 6.51% DexCom 19.31% 33.33% 13.19%

Does the media favor ITGR or DXCM?

In the previous week, DexCom had 17 more articles in the media than Integer. MarketBeat recorded 19 mentions for DexCom and 2 mentions for Integer. DexCom's average media sentiment score of 0.93 beat Integer's score of 0.84 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DexCom (DXCM) Competitors

$76.35 +1.39 (+1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$75.97 -0.38 (-0.50%)

As of 08:00 PM Eastern

Compare

DXCM vs. HQY, PODD, ABT, AMN, and ITGR

Should you buy DexCom stock or one of its competitors? MarketBeat compares DexCom with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DexCom include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), and Integer (ITGR). These companies are all part of the "medical" sector.

How does DexCom compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	6.09	$215.20M	$2.67	35.83
DexCom	$4.66B	6.32	$836.30M	$2.34	32.63

HealthEquity has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

HealthEquity presently has a consensus target price of $110.57, suggesting a potential upside of 15.59%. DexCom has a consensus target price of $84.88, suggesting a potential upside of 11.17%. Given HealthEquity's higher probable upside, equities research analysts clearly believe HealthEquity is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

DexCom has a net margin of 19.31% compared to HealthEquity's net margin of 17.25%. DexCom's return on equity of 33.33% beat HealthEquity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.25%	14.75%	9.22%
DexCom	19.31%	33.33%	13.19%

In the previous week, DexCom had 12 more articles in the media than HealthEquity. MarketBeat recorded 19 mentions for DexCom and 7 mentions for HealthEquity. DexCom's average media sentiment score of 0.93 beat HealthEquity's score of 0.82 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.6% of HealthEquity shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.6% of HealthEquity shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

DexCom beats HealthEquity on 12 of the 17 factors compared between the two stocks.

How does DexCom compare to Insulet?

DexCom (NASDAQ:DXCM) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

97.8% of DexCom shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
Insulet	10.44%	26.87%	12.01%

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	6.32	$836.30M	$2.34	32.63
Insulet	$2.71B	4.14	$247.10M	$4.30	37.69

In the previous week, Insulet had 31 more articles in the media than DexCom. MarketBeat recorded 50 mentions for Insulet and 19 mentions for DexCom. DexCom's average media sentiment score of 0.93 beat Insulet's score of 0.23 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	8 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

DexCom currently has a consensus target price of $84.88, suggesting a potential upside of 11.17%. Insulet has a consensus target price of $235.25, suggesting a potential upside of 45.16%. Given Insulet's higher probable upside, analysts clearly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89
Insulet	2 Sell rating(s)	4 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.71

DexCom has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Insulet has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Summary

DexCom beats Insulet on 11 of the 17 factors compared between the two stocks.

How does DexCom compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Abbott Laboratories has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

DexCom has a net margin of 19.31% compared to Abbott Laboratories' net margin of 13.90%. DexCom's return on equity of 33.33% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	13.90%	17.62%	10.01%
DexCom	19.31%	33.33%	13.19%

Abbott Laboratories presently has a consensus target price of $118.42, indicating a potential upside of 28.69%. DexCom has a consensus target price of $84.88, indicating a potential upside of 11.17%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, research analysts clearly believe Abbott Laboratories is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.93
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	3.62	$6.52B	$3.57	25.77
DexCom	$4.66B	6.32	$836.30M	$2.34	32.63

In the previous week, Abbott Laboratories had 17 more articles in the media than DexCom. MarketBeat recorded 36 mentions for Abbott Laboratories and 19 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.29 beat DexCom's score of 0.93 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	28 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Abbott Laboratories beats DexCom on 9 of the 17 factors compared between the two stocks.

How does DexCom compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

DexCom has a net margin of 19.31% compared to AMN Healthcare Services' net margin of -0.95%. DexCom's return on equity of 33.33% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
DexCom	19.31%	33.33%	13.19%

In the previous week, DexCom had 2 more articles in the media than AMN Healthcare Services. MarketBeat recorded 19 mentions for DexCom and 17 mentions for AMN Healthcare Services. DexCom's average media sentiment score of 0.93 beat AMN Healthcare Services' score of 0.38 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
DexCom	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AMN Healthcare Services currently has a consensus price target of $27.00, suggesting a potential downside of 20.52%. DexCom has a consensus price target of $84.88, suggesting a potential upside of 11.17%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by company insiders. Comparatively, 0.3% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

DexCom has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.48	-$95.70M	-$0.87	N/A
DexCom	$4.66B	6.32	$836.30M	$2.34	32.63

AMN Healthcare Services has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Summary

DexCom beats AMN Healthcare Services on 15 of the 17 factors compared between the two stocks.

How does DexCom compare to Integer?

Integer (NYSE:ITGR) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Integer presently has a consensus target price of $99.29, suggesting a potential upside of 2.99%. DexCom has a consensus target price of $84.88, suggesting a potential upside of 11.17%. Given DexCom's stronger consensus rating and higher probable upside, analysts plainly believe DexCom is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

99.3% of Integer shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, DexCom had 17 more articles in the media than Integer. MarketBeat recorded 19 mentions for DexCom and 2 mentions for Integer. DexCom's average media sentiment score of 0.93 beat Integer's score of 0.84 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DexCom has a net margin of 19.31% compared to Integer's net margin of 7.64%. DexCom's return on equity of 33.33% beat Integer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	7.64%	12.83%	6.51%
DexCom	19.31%	33.33%	13.19%

Integer has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

DexCom has higher revenue and earnings than Integer. Integer is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	1.77	$102.81M	$4.01	24.04
DexCom	$4.66B	6.32	$836.30M	$2.34	32.63

Summary

DexCom beats Integer on 14 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXCM vs. The Competition

Export

Metric	DexCom	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.93B	$7.63B	$7.06B	$12.61B
Dividend Yield	N/A	1.32%	2.68%	8.00%
P/E Ratio	32.63	50.28	27.15	24.26
Price / Sales	6.32	76.45	526.88	94.41
Price / Cash	27.07	26.85	29.22	49.36
Price / Book	10.85	7.32	10.75	6.29
Net Income	$836.30M	$162.30M	$3.58B	$330.66M
7 Day Performance	5.48%	-2.02%	-2.10%	-2.41%
1 Month Performance	1.30%	0.19%	3.32%	-0.64%
1 Year Performance	-8.42%	4.13%	28.17%	20.09%

DexCom Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXCM DexCom	3.9406 of 5 stars	$76.35 +1.9%	$84.88 +11.2%	-10.1%	$28.93B	$4.66B	32.63	11,000	Positive News
HQY HealthEquity	3.8067 of 5 stars	$96.57 +1.3%	$110.57 +14.5%	-0.1%	$8.07B	$1.34B	36.17	2,814
PODD Insulet	4.6058 of 5 stars	$159.77 -2.9%	$237.83 +48.9%	-44.3%	$11.07B	$2.90B	37.16	5,400	Trending News Analyst Forecast
ABT Abbott Laboratories	4.9914 of 5 stars	$95.64 +0.3%	$118.42 +23.8%	-28.8%	$166.59B	$45.13B	26.79	115,000	Positive News Upcoming Earnings
AMN AMN Healthcare Services	1.7693 of 5 stars	$35.84 +3.1%	$27.00 -24.7%	+53.3%	$1.39B	$2.73B	N/A	2,664	Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXCM) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Competitors